Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug-Drug Interaction Concerns
- Hannan M. Braun,
- Jury Candelario,
- Courtney L. Hanlon,
- ,
- Jesse L. Clark,
- Judith S. Currier
- University of California,
- David Geffen School of Medicine at UCLA,
- Special Service for Groups,
- Geisel School of Medicine at Dartmouth,
- Universidad Peruana de Ciencias Aplicadas,
- School of Public Health, University of Texas
Research Output:
Contribution to journal
Article
Peer-reviewPublication Information
Output type
Research Output:
Contribution to journal
Article
Peer-reviewOriginal language
EnglishPages from-to (Number of pages)
Pages 371-375 (5 pages)Journal (Volume, Issue Number)
LGBT Health (Volume 4, Issue 5)Publication milestones
- Published - 10/2017
Publication status
Published - 10/2017
ISSN
2325-8292Publication IDs
- Scopus: 85031308064
- PubMed: 28876170
Abstract
Purpose: Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence. Methods: This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA. Results: Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns. Conclusion: Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration.
Funding Details
The authors thank the participants who contributed their time and experiences. The authors acknowledge Diane Preciado for her help with participant recruitment as well as Destin Cortez, Tatiana Pavon, and the staff at APAIT for their assistance throughout the study. This work was supported, in part, by the Doris Duke Charitable Foundation through a grant supporting the Doris Duke International Clinical Research Fellows Program at the University of California, San Francisco. H.M.B. is a Doris Duke International Clinical Research Fellow. This research was also supported by the National Institutes of Health grants R25 MH087222 to J.L.C., K23 AI110532 to J.E.L. and 5P30 AI028697, and by the Gilead Sciences Research Scholars Program in HIV award to J.E.L.
J.E.L. has served as consultant to Gilead Sciences and GSK, and the parent study was funded by a research grant from Gilead Sciences. J.S.C. receives research funding to UCLA from Thera-technologies. The remaining authors have no conflicts of interest to disclose.
FundersFunding numbers
Doris Duke International Clinical
-Gilead Sciences Research Scholars Program
-NIH
5P30 AI028697, R25 MH087222
NIAID
K23AI110532
DDCF
-Gilead Sciences
-UCSF
-GSK
-Access to documents
Publication metrics
Metrics
PlumX, opens in new tab
Citations
53
Captures
75
Sustainable Development Goals
SDG 3 Good Health and Well